JAK2 MUTATION, TNF-Α AND IL 6 PREDICT RESPONSE TO JAK INHIBITOR IN RHEUMATOID ARTHRITIS PATIENTS

被引：0
|
作者：
Hussein, Y. Adel Abdelsalam [1 ]
Sadeq, Y. [2 ]
机构：
[1] Mansoura Univ Hosp, Rheumatol, Mansoura, Egypt
[2] Mansoura Univ Hosp, Clin Pathol, Mansoura, Egypt
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Prognostic factors;
D O I：
10.1136/annrheumdis-2023-eular.840
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0358
引用
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [21] JAK2 Mutation Analysis in Patients with Abdominal Venous Thrombosis
    Hayek, K.
    Zhuang, Y.
    Mattson, J.
    Crisan, D.
    MODERN PATHOLOGY, 2014, 27 : 350A - 350A
  • [22] JAK2 Mutation Analysis in Patients with Abdominal Venous Thrombosis
    Hayek, K.
    Zhuang, Y.
    Mattson, J.
    Crisan, D.
    LABORATORY INVESTIGATION, 2014, 94 : 350A - 350A
  • [23] JAK2 mutation in 153 patients with known or suspected MPD
    Drum, L.
    Ibrahim, S.
    Liu, C.
    LABORATORY INVESTIGATION, 2007, 87 : 239A - 239A
  • [24] Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
    Kay, Jonathan
    Harigai, Masayoshi
    Rancourt, Josh
    Dickson, Christina
    Melby, Thomas
    Issa, Maher
    de la Torre, Inmaculada
    Isaka, Yoshitaka
    Cardoso, Anabela
    Saifan, Chadi
    Keystone, Edward C.
    van Vollenhoven, Ronald F.
    Giles, Jon T.
    Huizinga, Tom W. J.
    Kremer, Joel M.
    RMD OPEN, 2020, 6 (03):
  • [25] Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study
    Dougados, Maxime
    van der Heijde, Desiree
    Chen, Ying-Chou
    Greenwald, Maria
    Drescher, Edit
    Liu, Jiajun
    Beattie, Scott
    de la Torre, Inmaculada
    Rooney, Terence
    Schlichting, Douglas
    De Bono, Stephanie
    Emery, Paul
    Bookman, Arthur
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1188 - 1188
  • [26] BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CDMARD THERAPY: RESULTS OF THE PHASE 3 RA-BUILD STUDY
    Dougados, M.
    van der Heijde, D.
    Chen, Y. -C.
    Greenwald, M.
    Drescher, E.
    Liu, J.
    Beattie, S.
    de la Torre, I.
    Rooney, T.
    Schlichting, D.
    de Bono, S.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 79 - 79
  • [27] THE EFFECTS OF TREATMENT RESPONSE AND RISK FACTOR TO INHIBIT THE CLINICAL RESPONSE IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS TREATED WITH IL-6 RECEPTOR INHIBITOR, ABATACEPT AND JAK INHIBITOR
    Anno, S.
    Okano, T.
    Mandai, K.
    Orita, K.
    Yamada, Y.
    Mamoto, K.
    Iida, T.
    Tada, M.
    Inui, K.
    Koike, T.
    Nakamura, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 390 - 390
  • [28] Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
    Choi, Wonho
    Ahn, Soo Min
    Kim, Yong Gil
    Lee, Chang-Keun
    Yoo, Bin
    Hong, Seokchan
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3238 - 3239
  • [29] COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE "JAK-POT" STUDY)
    Lauper, K.
    Mongin, D.
    Bergstra, S. A.
    Choquette, D.
    Codreanu, C.
    De Cock, D.
    Dreyer, L.
    Elkayam, O.
    Hyrich, K.
    Iannone, F.
    Inanc, N.
    Kristianslund, E.
    Kvien, T. K.
    Leeb, B.
    Lukina, G.
    Nordstrom, D.
    Pavelka, K.
    Pombo-Suarez, M.
    Rotar, Z.
    Santos, M. J.
    Strangfeld, A.
    Courvoisier, D.
    Finckh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 146 - 147
  • [30] Comparative effectiveness of JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors in an international collaboration of registers of rheumatoid arthritis patients (the "JAK-pot" study)
    Lauper, K.
    Mongin, D.
    Bergstra, S. A.
    Choquette, D.
    Catalin, Codreanu
    De Cock, D.
    Lene, Dreyer
    Elkayam, O.
    Hyrich, K.
    Iannone, F.
    Inanc, N.
    Kristianslund, E.
    Kvien, T. K.
    Leeb, B.
    Lukina, G.
    Nordstrom, D.
    Pavelka, K.
    Pombo Suarez, M.
    Rotar, Z.
    Santos, M. J.
    Strangfeld, A.
    Courvoiser, D. S.
    Finckh, A.
    SWISS MEDICAL WEEKLY, 2020, : 8S - 8S
12345